AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome
Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndrome
Presentations underscore significant need and opportunity for studying Alzheimer’s disease-like symptoms in this high-risk and genetically homogeneous population
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced initial interim data from an ongoing Phase 1b trial of the ACI-24 anti-Abeta vaccine to treat Alzheimer’s disease (AD) like symptoms in subjects with Down syndrome (DS) as well as key takeaways from its Key Opinion Leader (KOL) meeting, held in New York City.